Impact of polymorphisms in xeno(endo)biotic metabolism on pattern and frequency of p53 mutations in bladder cancer

Mutation Research - Reviews in Mutation Research

Volumn 462, Issue 2-3, 2000, Pages 303-309

  Martone, Tiziana ^a,b   Vineis, Paolo ^a   Malaveille, Christian ^c   Terracini, Benedetto ^a  

^a Unit of Cancer Epidemiology   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Bladder cancer; Metabolic polymorphisms; p53 Mutations

Indexed keywords

ARYL SULFOTRANSFERASE; CATECHOL METHYLTRANSFERASE; GLUTATHIONE TRANSFERASE; MYELOPEROXIDASE; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ADULT; AGED; ARTICLE; BLADDER CANCER; CLINICAL ARTICLE; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; MALE; MUTATION; MUTATION RATE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR BIOPSY; XENOBIOTIC METABOLISM;

AGED; ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; CATECHOL O-METHYLTRANSFERASE; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; MUTATION; NAD(P)H DEHYDROGENASE (QUINONE); POLYMORPHISM, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; XENOBIOTICS;

EID: 0034110882     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5742(00)00013-2     Document Type: Article

References (37)

1. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor-suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
2. Taylor J.A., Li Y., Mason T., Mettlin C., Vogler W.J., Maygarden S., Liu E. p53 Mutations in bladder tumors from arylamine-exposed workers. Cancer Res. 55:1996;294-298.
3. Martone T., Airoldi L., Magagnotti C., Coda R., Randone D., Malaveille C., Avanzi G., Merletti F., Hautefeuille A., Vineis P. 4-Aminobiphenyl-DNA adducts and p53 mutations in bladder cancer. Int. J. Cancer. 75:1998;512-516.
4. Brockmöller J., Kaiser R., Kerb R., Cascorbi I., Jaeger V., Roots I. Polymorphic enzymes of xenobiotic metabolism as modulators of acquired p53 mutations in bladder cancer. Pharmacogenetics. 6:1996;535-545.
5. Esteve A., Sorlie T., Martel Planche G., Hollstein M., Kusters I., Lewalter J., Vineis P., Stephan-Odenthal M., Montesano R. Screening for p53 gene mutations in archived tumors of workers occupationally exposed to carcinogens: examples from analysis of bladder tumors. J. Occup. Environ. Med. 37:1995;59-68.
6. Esrig D., Iii Spruck C.H., Nichols P.W., Chaiwun B., Steven K., Groshen S., Chen S.C., Skinner D.G., Jones P.A., Cole R.J. p53 Nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade and stage in bladder cancer. Am. J. Pathol. 143:1993;1389-1397.
7. Vet J.A.M., Bringuier P.P., Poddighe P.J., Karthaus H.F.M., Debruyne F.M.J., Schalken J.A. p53 Mutations have no additional prognostic value over stage in bladder cancer. Br. Med. J. 70:1994;496-500.
8. Coles B., Ketterer B. The role of glutathione and glutathione transferases in chemical carcinogenesis. Crit. Rev. Biochem. Mol. Biol. 25:1990;47-70.
9. Vineis P., Boffetta P., Cuzick J., Caporaso N., Malats N., D'errico A., Lang M. Metabolic polymorphisms and susceptibility to cancer in humans. IARC Sci. Publ. 145:1999.
10. Cascorbi I., Brockmöller J., Mrozikiewicz P.M., Müller A., Roots I. Arylamine N-acetyltransferase activity in man. Drug Metab. Rev. 31:1999;489-502.
11. Minchin R.F., Reeves P.T., Teitel C.H., Mcmanus M.E., Mojarrabi B., Ilett K.F., Kadlubar F.F. N- and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferase expressed in COS-1 cells. Biochem. Biophys. Res. Commun. 185:1992;839-844.
12. Zhu B.T., Conney A.H. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis. 19:1998;1-27.
13. Zhu B.T., Ezell E.L., Liehr J.G. Catechol-O-methyltransferase-catalyzed rapid O-methylation of mutagenic flavonoids. Metabolic inactivation as a possible reason for their lack of carcinogenicity in vivo. J. Biol. Chem. 269:1994;292-299.
14. Cavalieri E.L., Stack D.E., Devanesan P.D., Todorovic R., Dwivedy I., Higginbotham S., Johansson S.L., Patil K.D., Gross M.L., Gooden J.K., Ramanthan R., Cerny R.L., Rogan E.G. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc. Natl. Acad. Sci., U.S.A. 94:1997;10937-10942.
15. Malaveille C., Hautefeuille A., Pignatelli B., Talaska G., Vineis P., Bartsch H. Dietary phenolics as anti-mutagens and inhibitors of tobacco-related DNA adduction in the urothelium of smokers. Carcinogenesis. 17:1996;2193-2200.
16. Syvanen A.C., Tilgmann C., Rinne J., Ulmanen I. Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and Parkinsonian patients in Finland. Pharmacogenetics. 7:1997;65-71.
17. Jaiswal A.K. Human NAD(P)H: quinone oxidoreductase (NQO1) gene structure and induction by dioxin. Biochemistry. 30:1991;10647-10653.
18. Cadenas E. Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism. Biochem. Pharmacol. 49:1995;127-140.
19. Traver R.D., Horikoshi T., Danenberg K.D., Stadlbauer T.H., Danenberg P.V., Ross D., Gibson N.W. NAD(P)H: quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res. 52:1992;797-802.
20. Schulz W.A., Krummeck A., Rosinger I., Eickelmann P., Neuhaus C., Ebert T., Schmitz-Drager B.J., Sies H. Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics. 7:1997;235-239.
21. Miller J.A. Sulfonation in chemical carcinogenesis - history and present status. Chem. Biol. Interact. 92:1994;329-341.
22. Chou H.-C., Lang N.P., Kadlubar F.F. Metabolic activation of the N-hydroxy arylamines and N-hydroxy heterocyclic amines by human sulfotransferase(S). Cancer Res. 55:1995;525-529.
23. Hofstra A.H., Uetrecht J.P. Myeloperoxidase-mediated activation of xenobiotics by human leukocytes. Toxicology. 82:1993;221-242.
24. Mallet W.G., Mosebrook D.R., Trush M.A. Activation of (±)-trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene to diolepoxides by human polymorphonuclear leukocytes or myeloperoxidase. Carcinogenesis. 12:1991;521-524.
25. Kadlubar F.F., Butler M.A., Kaderlik K.R., Chou H.-C., Lang N.P. Polymorphisms for aromatic amine metabolism in humans: revelance for human carcinogenesis. Environ. Health Perspect. 98:1992;69-74.
26. Bell D.A., Taylor J.A., Butler M.A., Stephens E.A., Wiest J., Brubaker D.H., Kadlubar F.F., Lucier G.W. Genotype/phenotype discordance for human N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis. 14:1993;1689-1692.
27. International Pancreatic Disease Study Group, Bartsch H., Malaveille C., Lowenfels B., Maisonneuve P., Hautefeuille A., Boyle P. Genetic polymorphisms of N-acetyltransferases, glutathione-S-transferase M1 and NAD(P)H: quinone oxidoreductase in relation to malignant and benign pancreatic disease risk. Eur. J. Cancer Prev. 7:1998;215-223.
28. Peluso M., Airoldi L., Munnia A., Martone T., Coda R., Malaveille C., Giacomelli G., Terrone C., Casetta G., Vineis P. White blood cell DNA adducts, smoking, and NAT2 and GSTM1 genotypes in bladder cancer: a case-control study. Cancer Epidemiol., Biomarkers Prev. 7:1998;341-346.
29. Pemble S., Schroeder K.R., Spencer S.R., Meyer D.J., Hallier E., Bolt H.M., Ketterer B., Taylor J.B. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem. J. 300:1994;271-276.
30. Saarikoski S.T., Voho A., Reinikainen M., Anttila S., Karjalainen A., Malaveille C., Vainio H., Husgafvel-Pursiainen K., Hirvonen A. Combined effect of polymorphic GST genes on individual susceptibility to lung cancer. Int. J. Cancer. 77:1998;516-521.
31. Ozawa S., Tang Y.-M., Yamazoe Y., Kato R., Lang N.P., Kadlubar F.F. Genetic polymorphisms in human liver phenol sulfotransferases involved in the bioactivation of N-hydroxy derivatives of carcinogenic arylamines and heterocyclic amines. Chem.-Biol. Interact. 109:1998;237-248.
32. Hoda F., Nicholl D., Bennett P., Arranz M., Aitchinson K.J., al-Chalabi A., Kunugi H., Vallada H., Leigh P.N., Chaudhuri K.R., Collier D.A. No association between Parkinson's disease and low-activity alleles of catechol-O-methyl-transferase. Biochem. Biophys. Res. Commun. 21:1996;780-784.
33. T.J. Monks, S.S. Lau, Glutathione conjugate mediated toxicities, in: F.C. Kauffman (Ed.), Handbook of Experimental Pharmacology: Conjugation-Deconjugation Reactions in Drug Metabolism and Toxicity, Vol. 112, Springer-Verlag, New York, 1999, pp. 459-509.
34. 2 with intracellular glutathione and enhancement of its antiproliferative activity by glutathione depletion. Cancer Res. 50:1990;1879-1885.
35. Sato Y., Fujii S., Fujii Y., Kaneko T. Antiproliferative effects of glutathione S-transferase inhibitors on the K562 cell line. Biochem. Pharmacol. 39:1990;1263-1266.
36. 2 with glutathione, catalzyed by the human glutathione S-transferases A1-1, A2-2, M1a-1a and P1-1. Res. Toxicol. 10:1997;310-317.
37. Lombardi P.E., Mayhew J.W., Goldin B.R., Lynch M.A., Sullivan C.E., Gorbach S.L. Enzymatic methylation of microsomal metabolites of benzo(a)pyrene. Cancer Res. 41:1981;4415-4419.